India partially lifts API export restrictions

Published: 7-Apr-2020
Ingredients Regulatory

The Indian government has lifted restrictions on 13 APIs but imposed new restrictions on hydrochloroquine

The Directorate General of Foreign Trade (DGFT) in India has lifted the export restrictions on most APIs and their formulations. These products had previously been limited to ensure the country did not incur any shortages due to the global pandemic and reliance on China for raw materials.

Now China is recovering from the peak of its outbreak, the Indian government has now revised the export policy of these ingredients from 'Restricted' to 'Free'. These APIs included paracetamol and common antibiotics.

Conversely a few days prior to this, the country said it will no longer allow hydroxychloroquine or diagnostic kits to be exported.

There has been no evidence that hydroxychloroquine works against coronavirus yet, but it among many existing drugs that are under investigation for efficacy.

See more

You may also like

Regulatory

Overcoming CMC challenges in cell and gene therapy: part II

Read more
Certara’s Dr Hien Anh Bruno, Associate Director, Chemistry, Manufacturing and Controls (CMC), and Dr Deven Shah, CMC Lead, propose mitigation strategies to address the CMC challenges inherent in producing cell and gene therapy (CGT) drugs

Trending Articles

  1. Overcoming CMC challenges in cell and gene therapy: part I Certara’s Dr Hien Anh Bruno, Associate Director, Chemistry, Manufacturing and Controls (CMC), and Dr Deven Shah, CMC Lead, propose mitigation strategies to address the CMC challenges inherent in producing cell and gene therapy (CGT) drugs
  2. Causes and solutions for dark spots in tablet manufacturing Natoli Engineering examines the causes and solutions for dark spots that can halt production
  3. Assessing the risks: the importance of a multifaceted approach to containment Risk assessment is a crucial component of any manufacturing process and plays a key role in terms of ensuring the well-being of workers and the quality of products, reports Gabriela Mikhaiel, Global Marketing and Communication Manager at Dec Group
  4. The rising importance of preservative efficacy testing When considering the regulation and validation of pharmaceutical products, the efficacy of the active pharmaceutical ingredient (API) is often the main concern
  5. CordenPharma & GENEPEP collaborate to leverage peptide drug substance discovery The partnership has facilitated the expedition of the development, discovery and manufacturing of peptides for early clinical phase

Upcoming event

Cleanroom Conference UK

22–23 May 2024 | Exhibition | Birmingham, UK See all

You may also like

Regulatory

Overcoming CMC challenges in cell and gene therapy: part II

Certara’s Dr Hien Anh Bruno, Associate Director, Chemistry, Manufacturing and Controls (CMC), and Dr Deven Shah, CMC Lead, propose mitigation strategies to address the CMC challenges inherent in producing cell and gene therapy (CGT) drugs
Regulatory

Overcoming CMC challenges in cell and gene therapy: part I

Certara’s Dr Hien Anh Bruno, Associate Director, Chemistry, Manufacturing and Controls (CMC), and Dr Deven Shah, CMC Lead, propose mitigation strategies to address the CMC challenges inherent in producing cell and gene therapy (CGT) drugs
Regulatory

AskBio receives FDA Fast Track Designation for congestive heart failure gene therapy programme

The fast-tracking allows the development and expedition of review processes for AB-1002, a gene therapy to promote production of a constituently active form of I-1c
Manufacturing

CordenPharma & GENEPEP collaborate to leverage peptide drug substance discovery

The partnership has facilitated the expedition of the development, discovery and manufacturing of peptides for early clinical phase
Manufacturing

Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success

Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for successful market entry from the early stages of development, reports Frederick Duynslaeger, Senior CMC Writer at Ardena
Regulatory

Isospec Analytics launches biomolecular analysis technology to identify unknown molecules

The novel technology optimises the identification process of unknown molecules compared to mass analysis
Regulatory

4SC AG receives Paediatric Investigation Plan waiver for resminostat from the UK MHRA

The waiver allows the company to avoid investigating the CTCL drug in a paediatric population, as it's considered unnecessary or inappropriate for use by this patient group
Subscribe now